Rocket Pharmaceuticals RCKT Stock
Rocket Pharmaceuticals Price Chart
Rocket Pharmaceuticals RCKT Financial and Trading Overview
Rocket Pharmaceuticals stock price | 5.12 USD |
Previous Close | 22.69 USD |
Open | 22.47 USD |
Bid | 0 USD x 800 |
Ask | 0 USD x 800 |
Day's Range | 22.15 - 22.76 USD |
52 Week Range | 9.97 - 24.53 USD |
Volume | 655.04K USD |
Avg. Volume | 744.96K USD |
Market Cap | 1.83B USD |
Beta (5Y Monthly) | 1.211971 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.73 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 51.91 USD |
RCKT Valuation Measures
Enterprise Value | 1.52B USD |
Trailing P/E | N/A |
Forward P/E | -10.532407 |
PEG Ratio (5 yr expected) | 0.04 |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 3.9863327 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | -6.355 |
Trading Information
Rocket Pharmaceuticals Stock Price History
Beta (5Y Monthly) | 1.211971 |
52-Week Change | 106.06% |
S&P500 52-Week Change | 20.43% |
52 Week High | 24.53 USD |
52 Week Low | 9.97 USD |
50-Day Moving Average | 20.17 USD |
200-Day Moving Average | 18.76 USD |
RCKT Share Statistics
Avg. Volume (3 month) | 744.96K USD |
Avg. Daily Volume (10-Days) | 700.72K USD |
Shares Outstanding | 80.46M |
Float | 56.81M |
Short Ratio | 11.55 |
% Held by Insiders | 3.75% |
% Held by Institutions | 96.69% |
Shares Short | 7.9M |
Short % of Float | 13.28% |
Short % of Shares Outstanding | 9.81% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:4 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -31.21% |
Return on Equity (ttm) | -54.12% |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | N/A |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | N/A |
EBITDA | -239172992 USD |
Net Income Avi to Common (ttm) | -237216000 USD |
Diluted EPS (ttm) | -3.29 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 331.08M USD |
Total Cash Per Share (mrq) | 4.12 USD |
Total Debt (mrq) | 25.4M USD |
Total Debt/Equity (mrq) | 5.54 USD |
Current Ratio (mrq) | 10.832 |
Book Value Per Share (mrq) | 5.707 |
Cash Flow Statement
Operating Cash Flow (ttm) | -196479008 USD |
Levered Free Cash Flow (ttm) | -113579872 USD |
Profile of Rocket Pharmaceuticals
Country | United States |
State | NJ |
City | Cranbury |
Address | 9 Cedarbrook Drive |
ZIP | 08512 |
Phone | 609 659 8001 |
Website | https://rocketpharma.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 240 |
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. The company is headquartered in Cranbury, New Jersey.
Q&A For Rocket Pharmaceuticals Stock
What is a current RCKT stock price?
Rocket Pharmaceuticals RCKT stock price today per share is 5.12 USD.
How to purchase Rocket Pharmaceuticals stock?
You can buy RCKT shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Rocket Pharmaceuticals?
The stock symbol or ticker of Rocket Pharmaceuticals is RCKT.
Which industry does the Rocket Pharmaceuticals company belong to?
The Rocket Pharmaceuticals industry is Biotechnology.
How many shares does Rocket Pharmaceuticals have in circulation?
The max supply of Rocket Pharmaceuticals shares is 106.63M.
What is Rocket Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Rocket Pharmaceuticals PE Ratio is now.
What was Rocket Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Rocket Pharmaceuticals EPS is -2.73 USD over the trailing 12 months.
Which sector does the Rocket Pharmaceuticals company belong to?
The Rocket Pharmaceuticals sector is Healthcare.
Rocket Pharmaceuticals RCKT included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 15587.79 USD — |
-5.82
|
9.14B USD — | 15575.68 USD — | 16128.16 USD — | — - | 9.14B USD — |
NASDAQ Global Market Composite NQGM | 1647.83 USD — |
-5.17
|
— — | 1610.28 USD — | 1681.06 USD — | — - | — — |
NASDAQ Biotechnology NBI | 3904.12 USD — |
-5.49
|
— — | 3901.51 USD — | 4064.61 USD — | — - | — — |
NASDAQ HealthCare IXHC | 869.8 USD — |
-5.51
|
— — | 868.74 USD — | 900.72 USD — | — - | — — |
Nasdaq US 700 Small Cap Index NQUS700SC | 1938.96 USD — |
-4.51
|
— — | 1891.68 USD — | 1965.66 USD — | — - | — — |
Stlmt ID NASDAQ Biotechnology NBX | 4153.28 USD — |
+1.21
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
- {{ link.label }} {{link}}